Member Info for Ivyspivey

Evening,Yes thanks to everyone for continuing to try and get to the bottom of this absolute mess and great work tonight the Gambler.
We know we take risks when we invest on AIM and most are prepared to take the proverbial rough with the smooth.
Blatant criminality and incompetence are hard to digest and sometimes it may not be their original intention but there is a huge streak of arrogance amongst the various bedfellows which is slowly being unearthed.
As I have said before I moved along from this a long time ago and just to chalk it down to experience and try and learn lessons to benefit from it.
Great credit to all the sleuths who continue to try and unravel this can of worms and although not hopeful if something can be salvaged for the folk here who have lost a lot then I wish them all well

Oasis totally correct I do feel some are judging today’s RNS by the £3m figure and expecting it to be much higher.They seem to have forgot to include how much potential future income this CHIM will unlock in the global testing of Vax and AVs

2023

Hi Bermuda just posted that on other site
Only other change is completion date of Dec 1st 2923 rather than 30th Sept

WTP- I am sure the rules covering all of the BoD re closed periods are consistent whether NXDs or not and usually involve proximity to published results.There are of course other rules covering everyone about “ inside info” and using that for trading/ investing advantage. This info normally relates to material news and certainly all employees and BoD would be covered by internal regulations as well as the wider financial regulatory network.
If an NXD is appointed to provide a wider business perspective which is normally the case I would expect them to attend the regular board Meetings guess approx 6 tines a year with likes of SCLP and they would get a general update on such occasions and apart from EGMs I would not expect them to be aware of anything in particular operationally.
However as Vulpes via MD has a substantial SH and that is why he was mainly made an NXD Will outside of that role imo have very close contact with CH and probably like Redmile who are not on BoD are getting a report on progress at least monthly if not a shorter timeframe.
So I would not worry about whether any BoD buy or sell means news us or is not imminent just take it as a litmus test of general informed sentiment at a particular point in time

https://t.co/BsfJX0Vg5i

Very good day with returning confidence based on Vulpes buy.
I am sure in his NXD role he would not normally be involved in the day to day stuff however he is mainly on BoD imo as a major SH and if you recall John Glencross of Calculus in an interview once claim he was in regular contact with SCLP about what was happening then I am sure Martin Diggle will be equally as knowledgable about what is going on.
This is not about I owning it not knowing anything material but simply a confidence to add at this level

Yep excellent news about Diggle topping up at this level.Good sign of confidence

Morning,
Interesting discussion about IP but again agree it is important for small bios like SCLP to retain the IP as it is critical to encourage these outfits to continue to accelerate the science.
It is for bigger pharma/ govts/ philanthropic outfits to find ways to “ solve” these global issues or at least contribute to them.
But even boing pharma have other stakeholders to satisfy as have Govts so it is not always easy to simply do more even if this seems an easy choice for others to call for

Hi Crumbs.Absolutely.

LL Not expecting anything tomorrow as CH has been away this week.

Autonomy pleased that you have decided not to sell as I do think the science here is great and at some point will be rewarded as one or more of the multiple shots at goal hits the back of the net.If you have bought in recently then you will share the frustration of many LTH who have endured the ups and downs of being invested here.
I have to say though that many of the LTH are in a pretty decent position as their averages would be so much lower based on their confidence in buying a lot at much lower levels.
As Kashdog says and in fact the BoD have stated on many occasions it is the validation of the science with data that will lead to monetisation of the science that is key here and the pace of progress towards that is usually at the dispute of differing views on here
ATB

Has not copied crossing outs but as Crumbs says U.K. gone to worldwide and as MiaVoce says plan has gone from 2 years to 25 weeks

Hi Crumbs Key changes

This study is expected to enrol approximately 25 melanoma patients from the UK worldwide.

Detailed Description: This is an open label, single arm Phase 2 study to determine the safety and tolerability of SCIB1 administered to patients with advanced melanoma using an electroporation device (the TDS-IM v2.0 device) when added to pembrolizumab (Keytruda), a standard treatment already approved for the treatment of advanced melanoma.
The plan for this research study is for SCIB1 to be given for up to 2 years 25 weeks, in combination with pembrolizumab according to the current label.

After receiving the first dose of SCIB1, the patient will then receive SCIB1 3 another 4 times at 4, 3 weeks apart 7, then once 6 13 and 25 weeks later, and . Pembrolizumab treatment will be started 1 week after that once the first dose of SCIB1 and given every 12 6 weeks until the treatment is stopped .

Thanks Miavoce
Funny I looked on CT site this morning to answer WTPs question and last entry was July 20 but as you say it has been updated today from 26 th

https://clinicaltrials.gov/ct2/history/NCT04079166?V_4=View#StudyPageTop

Been no update to official SCIB 1 Combo trial since 27th July last tear

Hi Ruck.I would be disappointed if multiple “ penalty’s “ did not hit the back of the net.That sums up my confidence re multiple shots on goal rather than random half chances.
Krafty- most if my comment re pharma was aimed at wider portfolio rather than specifically Covidity.
My thoughts on the Covid Vax would be a pharma partner would not get formally involved without some human clinical data and this is a different situation as to when the first generation Vax were at the same stage.
There is a complete need for a Universal Covid Vax but I don’t think that the next announcement will be one with all the details of a partner etc.
I think it will be confirmation of completing all the preparation and entering p1 trials.That in itself is a huge step and my gut feel is just takes time to get the preparations ready in a timely way such as booking of slots,regulatory Approval,completion of delivery system etc.
I would love to be wrong and a huge announcement is made with all bells and whistles and that is why I would like an update to clarify what is happening on the ground

Yep Trebor,
I don’t worry about being “ left on the shelf” as the data as we constantly told will determine the outcome here and I am confident that any interested parties will have access to data that perhaps we as PIs don’t see such as full pre clinical data.
Pharma today will do partnership deals based on the science but largely the risk is with the smaller party.They require in the main more than “ compelling science” unless it replaces or very complementary to what they are already doing as part of their strategic vision.
As you say we need to progress these into producing trial data and lack of news will inevitably restrict SP movement. I don’t agree this a lifestyle BoD but I think they are cautious when it comes to releasing news hence often a wait and u til the news is announced we have to be oatient.
But multiple shots at goal

Hi Krafty,
We all know Lindy is a real top expert with regard to immune response and the SCLP Approach is unique and scientifically very robust to providing a possible universal Covid Vax candidate.
Like others I would just like to see an update as to where we are in the process and ideally a bit more flesh on the bone re confirming SN15 and delivery system are about to enter p1 and more detailed ore clinical response

To make a universal SARS-CoV-2 vaccine that provides long-term protection, we may need to think beyond the spike, Baozhong Wang, a biologist at Georgia State University, says. “Broad, neutralizing antibodies to conserved areas in spike protein are important, but not the whole” solution, Wang says. T-cell responses in the lungs will be crucial, too, because they catalog memories of past respiratory viral pathogens. These responses are predominantly induced by proteins inside the virus, Wang explains, such as the nucleoproteins and enzymes that help it reproduce, rather than its spike.